BCMA-CD3 bispecific

Clinical trials for BCMA-CD3 bispecific explained in plain language.

Never miss a new study

Get alerted when new BCMA-CD3 bispecific trials appear

Sign up with your email to follow new studies for BCMA-CD3 bispecific, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Completed 1

New drug shows promise for Hard-to-Treat blood cancer

Disease control Completed

This study tested a drug called elranatamab in 39 Chinese patients with multiple myeloma that had stopped responding to at least three prior treatments. The drug works by helping the immune system attack cancer cells. The goal was to see if it could shrink tumors and control the …

Matched conditions: BCMA-CD3 BISPECIFIC

Phase 2 • Sponsor: Pfizer • Aim: Disease control

Last updated Jun 27, 2026 08:09 UTC

BCMA-CD3 bispecific

Get alerted when new BCMA-CD3 bispecific trials appear

New drug shows promise for Hard-to-Treat blood cancer